Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 576
- Registration Number
- NCT00389207
- Locations
- 🇲🇽
1100.1470.55001 Boehringer Ingelheim Investigational Site, Col. Toriello Guerra, Mexico
🇵🇹1100.1470.35103 Boehringer Ingelheim Investigational Site, Porto, Portugal
🇨🇭1100.1470.41002 Boehringer Ingelheim Investigational Site, Zürich, Switzerland
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 327
- Registration Number
- NCT00388882
- Locations
- 🇺🇸
205.346.105 Boehringer Ingelheim Investigational Site, Charleston, South Carolina, United States
🇦🇷205.346.509, Rosario, Santa Fe, Argentina
🇦🇷205.346.511, Rosario, Santa Fé, Argentina
Tiotropium / Respimat One Year Study in COPD.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Device: Respimat
- First Posted Date
- 2006-10-12
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3991
- Registration Number
- NCT00387088
- Locations
- 🇺🇸
205.372.01028 Boehringer Ingelheim Investigational Site, Rancho Mirage, California, United States
🇺🇸205.372.01060 Boehringer Ingelheim Investigational Site, Clearwater, Florida, United States
🇺🇸205.372.01008 Boehringer Ingelheim Investigational Site, Norwalk, Connecticut, United States
Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer
- First Posted Date
- 2006-09-15
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT00376623
- Locations
- 🇩🇪
1216.9.49001 Boehringer Ingelheim Investigational Site, Heidelberg, Germany
🇩🇪1216.9.49002 Boehringer Ingelheim Investigational Site, Freiburg, Germany
🇩🇪1216.9.49007 Boehringer Ingelheim Investigational Site, Gauting, Germany
A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2006-09-12
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 404
- Registration Number
- NCT00375284
- Locations
- 🇺🇸
248.616.035 Boehringer Ingelheim Investigational Site, Mesa, Arizona, United States
🇺🇸248.616.049 Boehringer Ingelheim Investigational Site, Augusta, Georgia, United States
🇺🇸248.616.066 Boehringer Ingelheim Investigational Site, Savannah, Georgia, United States
An Efficacy and Safety Evaluation of Tiotropium add-on Therapy in Patients With Severe Persistent Asthma
- Conditions
- Asthma
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 115
- Registration Number
- NCT00365560
- Locations
- 🇳🇱
lokatie het Spittaal, Zutphen, Netherlands
🇳🇱Polikliniek longziekten, Hengelo, Netherlands
🇩🇪Boehringer Ingelheim Investigational Site, Wiesloch, Germany
A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 349
- Registration Number
- NCT00359788
- Locations
- 🇺🇸
205.325.935 Boehringer Ingelheim Investigational Site, Fort Collins, Colorado, United States
🇺🇸205.325.917 Boehringer Ingelheim Investigational Site, Buffalo, New York, United States
🇺🇸205.325.924 Boehringer Ingelheim Investigational Site, East Orange, New Jersey, United States
Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances
- Conditions
- Restless Legs SyndromeDepression
- First Posted Date
- 2006-07-25
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 404
- Registration Number
- NCT00356096
- Locations
- 🇫🇮
248.604.35801 Boehringer Ingelheim Investigational Site, Espoo, Finland
🇰🇷248.604.82003 Boehringer Ingelheim Investigational Site, Incheon, Korea, Republic of
🇮🇹248.604.3909 IRCCS Fondazione "Salvatore Maugeri", Telese Terme (be), Italy
Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg
- Conditions
- Asthma
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 388
- Registration Number
- NCT00350207
- Locations
- 🇧🇪
205.342.32003 Boehringer Ingelheim Investigational Site, Herentals, Belgium
🇦🇹205.342.43005 Boehringer Ingelheim Investigational Site, Wien, Austria
🇧🇪205.342.32002 Boehringer Ingelheim Investigational Site, Brussel, Belgium
A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2006-07-07
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 369
- Registration Number
- NCT00349531
- Locations
- 🇬🇧
248.615.44009 Boehringer Ingelheim Investigational Site, Reading, United Kingdom
🇪🇸248.615.3404 Hospital General Universitario Gregorio Marañón, Madrid, Spain
🇪🇸248.615.3408 Hospital Nuestra Señora de Sonsoles, Avila, Spain